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Introduction and Background: IL-17 pathway is being clinically 
targeted in immune-mediated diseases, most of which are associated 
with a significant cardiovascular risk. We investigated the relation-
ship between serum levels of IL-17 and the risk of cardiovascular 
events in patients with acute myocardial infarction.
Patients (or Materials) and Methods: We used data from patients 
enrolled in the prospective, multicenter French registry of acute 
ST elevation or non–ST-elevation myocardial Infarction (Fast-MI, 
NCT00673036). Of the 374 centers in France that treated patients 
with acute MI, 223 (60%) participated in the registry. Among these, 
100 centers recruited 1029 patients who contributed to a serum bank. 
Their baseline characteristics were comparable to the overall popu-
lation of the registry. Written informed consent was provided by 
each patient. More than 99% of patients were Caucasian. Two-year 
follow-up was > 98% complete.
Results: Serum levels of IL-17 were associated with the risk of all-
cause death and recurrent MI at 2 years, with levels of IL-17 below 
the median indicative of a worse outcome. The impact of IL-17 
remained significant after adjustment for known cardiovascular risk 
factors, CRP, and treatments including statins: hazard ratio (HR) = 
1.40 (1.03–1.91); P = 0.03.IL-17 inhibited mononuclear cell adhe-
sion to endothelium and reduced endothelial VCAM-1 expression. 
Patients with low (below the median) IL-17 levels and high (above 
the median) soluble VCAM-1 (sVCAM-1) levels were at particularly 
increased risk of death and MI: adjusted HR = 2.22 (1.32–3.75) 
compared with the high IL-17/low sVCAM-1 group (P = 0.002).
Conclusion: Low serum levels of IL-17 are associated with a higher risk 
of major cardiovascular events in Caucasian patients with acute MI. 
Our results raise possible concern about the use of inhibitors of IL-17 
pathway in clinical settings associated with a high cardiovascular risk.
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Introduction: Investigations based on quantitative sensory testing 
have consistently evidenced allodynia in FMS patients involving both 
spinal and supraspinal pain regulatory systems. Functional imaging 
studies have demonstrated enhanced neural activities in pain related 
brain areas as well as impairment of pain inhibition in the descending 
nociceptive regulatory system. Higher state of excitability of spinal 
nociceptive neurons as evidenced by lowered nociceptive flexion 
reflex R-III (NFR) threshold was reported for FMS patients. The NFR 
procedure has been shown to be a valuable tool to evaluate pharma-
cologically active therapeutic agents at the spinal level. Serotonin-
noradrenaline reuptake inhibitors have been shown to reduce pain 
in fibromyalgia syndrome patients possibly through descending 
monoaminergic pain pathways modulation. This randomized dou-
ble- blind, placebo-controlled trial assessed the pharmacodynamic 
activity of the dual-reuptake inhibitor milnacipran (MLN) at the 
spinal level by means of the objective spinal NFR.
Patients (or Materials) and Methods: Seven-week exposure (100, 
150, 200 mg/d) in female fibromyalgia patients. Evaluation consisted 
of extensive quantitative sensory testing, including determination of 
the nociceptive flexion reflex threshold (NFR), self-reported standard 
questionnaires investigating pain: visual analog scales; fibromyal-
gia impact, health-related quality of life, depression, and anxiety 
questionnaires as well as and Patient’s Global Impression of Change 
(PGIC). Analysis of covariance adjusted for baseline value was used 
for all end points.
Results: Seventy-seven (39 placebo, 38 milnacipran all doses) of 80 
randomized patients were available for analysis. The absence of influ-
ence of MLN (any dose) on the NFR surprisingly contrasted with the 
dose-dependent analgesic effect observed in MLN-treated patients 
with an adjusted change difference of –18.4 mm (–30.9; –5.8) in 
pain reduction between placebo and the maximum dosage (200 mg) 
MLN groups (P = 0.02). Unchanged depression and anxiety scores 
confirmed the predominant selectivity of the analgesic effect of MLN 
on nociceptive pain pathway. Self-reported questionnaires consist-
ently reflected the positive effects of MLN on quality of life and psy-
chological well-being. Odds ratio 5.1 for PGIC responders (ie, much/
very much improved) was significantly in favor of MLN (P = 0.04).
Conclusion: Milnacipran has a predominantly supraspinal analgesic 
effect as evidenced by the significant clinical benefits and the absence 
of changes in the nociceptive spinal reflex threshold. Higher dose 
was associated with higher pain reduction. Reported analgesia was 
independent of patients’ emotional status.
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Introduction: Oral or intravenous (IV) paracetamol (APAP) is used 
for mild to moderate pain but has a latency to be effective. When fast 
relief is required and oral/IV routes are not available because of the 
patient’s condition, the transmucosal buccal route may be an alterna-
tive. A new transmucosal buccal (b) pharmaceutical form of APAP 
that had been previously assessed in healthy volunteers is studied in 
patients admitted to hospital for acute pain.
Patients (or Materials) and Methods: A randomized double-
blind noninferiority clinical trial (NCT01586143) included 38 
patients admitted to the Accident and Emergency Department of 
Clermont-Fd University Hospital, France, for trauma of the upper 
or lower limb, and with pain intensity between 4 and 6 on a 0 to 10 
numerical scale (NS). Patients were injected at t0 over a 15-minute 
period with placebo (0.9% saline) or APAP (1 g) and concomitantly, 
125 mg of APAP dissolved in 1 mL of an hydroalcoholic solution 
(HAS) or placebo (HAS only) was applied in the left mucogingival 
sulcus. Patients were asked not to swallow for 1:30 minutes. NS 
evaluations were done at t10, t30, t120, and t180 minutes after 
administration. Primary end point was the pain intensity difference 
(PID) between t30 min and t0. PID of both arms were compared 
by Student t test with a P < 0.05 significance. Secondary end points 
were PID at other times.
Results: Results (mean [SD]) show no significant PID difference 
between bAPAP and ivAPAP, respectively: t10min (–0.9 [1.3] vs –1.3 
[1.8]), t30min (–2.0 [1.8] vs –2.4 [1.5]), t120min (–2.9 [1.9] vs –3.3 
[1.5]), t180 (–2.1 [2.2] vs –3.4 [1.8]; all P > 0.05).
Conclusion: Transmucosal buccal APAP has a similar analgesic effect 
than ivAPAP in patients admitted to hospital for acute trauma pain of 
mild to moderate intensity. The mechanism of action of this pharma-
ceutical form must now be studied further. This attractive alternative 
to other routes would be useful in situations where oral or IV routes 
are not available or in vulnerable populations (cancer pain, palliative 
care, geriatrics) for acute pain paroxysms.
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Introduction: The calcineurin inhibitor (CI) tacrolimus remains the 
mainstay of kidney transplant maintenance immunosuppression. In 
most patients, it is combined with mycophenolate mofetil (MPA) and 
corticosteroids. As part of an investigation of effect of drug–drug 
interactions in the setting of routine care, we investigated the effect 
of mycophenolate mofetil dose on the kinetics of tacrolimus.
Patients (or Materials) and Methods: We performed a retrospective 
analysis of TDM measurements in the past 5 years at a single trans-
plant center in the University Hospital in Olomouc, Czech Republic. 
More than 4000 measurements of trough concentrations (C0) of CIs 
and MPA were included in the analysis made in 111 male and 70 
female kidney transplant recipients (181 in total). Patients were aged 
13 to 72 years (average, 45.7). Average time from transplant was 5.6 
years (0.4 to 18).
Drug measurements were obtained from the hospital informa-
tion system, and information on prescription was ascertained from 
prescription database and patient clinical records (including dosing 
instructions and specific temporary instructions concerning co-pre-
scription of interacting medication). CI levels were expressed as nor-
malized dose (ND) required to reach a unit concentration and a linear 
regression model was constructed to quantify effects of various inter-
acting factors (eg, age, sex, prednisone dose, MPA dose, body weight).
Tacrolimus ND = a0-a1 × MPA + a2 × Tx-a3 × ATB-a4 × 
INTER + a5 × DOSE-a6 × AGE
Where MPA is the dose of mycophenolate mofetil in mg/kg body 
weight, Tx is time from transplantation in years, ATB is 1 if the 
patient is treated with an antimicrobial, INTER is 1 is the patient is 
treated with an interacting antimicrobial, DOSE is the dose of tac-
rolimus in μ g/kg of body weight, and AGE is patient’s age in years.
Results: The constructed model yielded the following statistically 
significant parameters: The coefficient for MPA dose means that for 
each 100 mg of MPA there was on average a 0.99 l/kg reduction in 
the dose of tacrolimus to reach a unit concentration (14%). Other 
significant factors included time from transplantation, interacting 
antimicrobials, and age (all, P < 0.001). 
Conclusion: Our data from routine clinical practice indicate the pres-
ence of a mycophenolate-mofetil and tacrolimus interaction. Some 
literature reports confirm this interaction, but data are still conflict-
ing, and more studies are needed to confirm its clinical significance.
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Introduction: According to the product information of imatinib, 
imatinib is mainly metabolized by CYP3A4. Because our recent 
in vitro findings indicate that CYP2C8 participates in imatinib 
N-demethylation2 and there are no clinical data concerning the role 
of CYP2C8 in its metabolism, we studied the effects of the strong 
CYP2C8 inhibitor gemfibrozil on the single-dose pharmacokinetics 
of imatinib in healthy volunteers.
Patients (or Materials) and Methods: In a randomized, crossover 
study, 10 healthy subjects were administered gemfibrozil 600 mg 
or placebo twice daily for 6 days, and imatinib 200 mg on day 3. 
The plasma concentrations of imatinib and its main metabolite 
N-desmethylimatinib (N-DMI) were determined using a liquid chro-
matography–tandem mass spectrometry system. The pharmacokinet-
ics of imatinib and N-DMI were calculated by noncompartmental 
analysis. Logarithmic transformation was used for pharmacokinetic 
variables, and statistical comparisons between the phases were made 
with the paired t test. Because imatinib may time dependently inhibit 
its own CYP3A4-mediated elimination,3 the obtained clinical data 
was then applied to a physiologically based pharmacokinetic (PBPK) 
model to predict the contribution of CYP2C8 to imatinib metabolism 
during multiple-dose administration.
Estimate Std. Error Significance
a0 (Intercept) 7.090e-03 1.965e-04 P < 0.001
a1 (MPA) –9.978e-04 1.326e-04 P < 0.001
a2 (Tx) 2.128e-04 1.890e-05 P < 0.001
a3 (ATB) –5.921e-04 2.644e-04 P < 0.01
a4 (INTER) –2.557e-03 5.149e-04 P < 0.001
a5 (DOSE) 1.522e-04 3.059e-06 P < 0.001
a6 (AGE) –2.533e-05 6.984e-06 P < 0.001
